Cervical dilatation with meteneprost vaginal suppositories in first trimester abortion.
Forty nulliparous women were treated with vaginal suppositories containing Meteneprost (9-deoxo-16, 16-dimethyl-9-methylene PGE2) (Upjohn Co.) 10 mg or placebo prior to termination of first trimester pregnancy in a double-blind study. The suppository was inserted three hours before vacuum aspiration. The cervical diameter as measured by the size of the largest Hegar dilatator inserted without resistance was significantly larger in women treated with Meteneprost. The operative blood loss was also reduced in the Meteneprost group.
Somell
C
C
Olund
A
A
D015064:16,16-Dimethylprostaglandin E2 / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology*; D000019:Abortifacient Agents / Q000494:pharmacology*; D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects / Q000494:pharmacology*; D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*; D011897:Random Allocation; D013488:Suppositories; D014592:Uterine Hemorrhage / Q000517:prevention & control; D014619:Vacuum Curettage / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D011459:Prostaglandins E, Synthetic; D013488:Suppositories; C025505:meteneprost; D015064:16,16-Dimethylprostaglandin E2